Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Behrens

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Radiation Protection Dosimetry|November 23, 2017
The ICRU Proposal for New Operational Quantities for External RadiationT Otto, N E Hertel, D T Bartlett, et al.
Biological Psychiatry|April 14, 2015
Structural Hippocampal Damage Following Anti-N-Methyl-D-Aspartate Receptor EncephalitisCarsten Finke, Ute A Kopp, Anna Pajkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)A D Wagner, P Buechner-Steudel, A Wein, et al.
Stroke|December 1, 1994
Body mass index and thromboembolic stroke in nonsmoking men in older middle age. The Honolulu Heart ProgramR D Abbott, G R Behrens, D S Sharp, et al.
Science (New York, N.Y.)|May 26, 2007
Dicamba resistance: enlarging and preserving biotechnology-based weed management strategiesMark R Behrens, Nedim Mutlu, Sarbani Chakraborty, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 28, 2016
Validity of visual perceptive computing for static posturography in patients with multiple sclerosisJanina R Behrens, Sebastian Mertens, Theresa Krüger, et al.
European Journal of Neurology|July 30, 2015
Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosisJanina R Behrens, Ludwig Rasche, Rene M Gieß, et al.
British Journal of Cancer|November 12, 2009
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trialsA D Wagner, P Buechner-Steudel, M Moehler, et al.
BMC Neurology|January 15, 2017
Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of lifeTheresa Krüger, Janina R Behrens, Anuschka Grobelny, et al.
The American Journal of Gastroenterology|November 30, 2000
Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic GroupT Andersson, E Hassall, P Lundborg, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Radiation Protection Dosimetry|November 23, 2017
The ICRU Proposal for New Operational Quantities for External RadiationT Otto, N E Hertel, D T Bartlett, et al.
Biological Psychiatry|April 14, 2015
Structural Hippocampal Damage Following Anti-N-Methyl-D-Aspartate Receptor EncephalitisCarsten Finke, Ute A Kopp, Anna Pajkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)A D Wagner, P Buechner-Steudel, A Wein, et al.
Stroke|December 1, 1994
Body mass index and thromboembolic stroke in nonsmoking men in older middle age. The Honolulu Heart ProgramR D Abbott, G R Behrens, D S Sharp, et al.
Science (New York, N.Y.)|May 26, 2007
Dicamba resistance: enlarging and preserving biotechnology-based weed management strategiesMark R Behrens, Nedim Mutlu, Sarbani Chakraborty, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 28, 2016
Validity of visual perceptive computing for static posturography in patients with multiple sclerosisJanina R Behrens, Sebastian Mertens, Theresa Krüger, et al.
European Journal of Neurology|July 30, 2015
Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosisJanina R Behrens, Ludwig Rasche, Rene M Gieß, et al.
British Journal of Cancer|November 12, 2009
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trialsA D Wagner, P Buechner-Steudel, M Moehler, et al.
BMC Neurology|January 15, 2017
Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of lifeTheresa Krüger, Janina R Behrens, Anuschka Grobelny, et al.
The American Journal of Gastroenterology|November 30, 2000
Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic GroupT Andersson, E Hassall, P Lundborg, et al.
Pageof 16